---
document_datetime: 2026-01-23 11:35:05
document_pages: 4
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/elahere-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
document_name: elahere-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 2.5168215
conversion_datetime: 2026-01-26 20:24:09.276284
docling_version:
  docling-serve: 1.10.0
  docling-jobkit: 1.8.1
  docling: 2.70.0
  docling-core: 2.60.2
  docling-ibm-models: 3.11.0
  docling-parse: 4.7.3
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## ELAHERE

Procedural steps taken and scientific information after the authorisation*

*Due to the Agency`s update of its procedure management systems, an additional document, reflecting the historical lifecycle may be available in the 'Assessment history' section. For the complete product lifecycle procedures, you may need to also refer to EPAR - Procedural steps taken and scientific information after authorisation (archive) .

| Application number                       | Scope                                              | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary   |
|------------------------------------------|----------------------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|-----------|
| Variation type IA_IN / EMA/VR/0000323227 | This was an application for a group of variations. | 22/01/2026                          |                                             | Annex II and PL                  |           |

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

|                                       | B.II.b.1 Replacement or addition of a manufacturing site for part or all of the manufacturing process of the finished product - B.II.b.1.a Secondary packaging site - Accepted B.II.b.2.c Replacement or addition of a manufacturer responsible for importation and/or batch release - B.II.b.2.c.1 Not including batch control/testing - Accepted                                                                                                                        |            |     |                       |
|---------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|-----------------------|
| Variation type II / EMA/VR/0000297255 | B.I.a.3 Change in batch size (including batch size ranges) of active substance or intermediate used in the manufacturing process of the active substance - B.I.a.3.c The change requires assessment of the comparability of a biological/immunological active substance - Accepted                                                                                                                                                                                        | 04/12/2025 | N/A |                       |
| Variation type IB / EMA/VR/0000286590 | C.I HUMAN AND VETERINARY MEDICINAL PRODUCTS - C.I.z Other variation - Accepted C.I.z. - to propose changes in sections 1, 2, 3, 4, 5 and 6 of the Package Leaflet following an assessment carried out on target patient groups. The MAH took the opportunity to make some editorial changes in the SmPC and additional editing amendments have been carried out in FI, DE, NO, PL, SL, ES and LT annexes. In addition, Annex II has been amended by reporting the correct | 20/08/2025 |     | SmPC, Annex II and PL |

<div style=\"page-break-after: always\"></div>

|                                       | manufacturer of the biological active substance: Bsp Pharmaceuticals S.p.A, Via Appia Km 65561, Latina Scalo, LT 04013 Italy. Finally, an editorial correction has been performed in the contact details of the Icelandic local representative in section 6 of the PL.                                                                                                                                                                                                                                                                                                                                                                                                                                                      |            |     |
|---------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|
| Variation type IA / EMA/VR/0000290386 | This was an application for a group of variations. B.II.e.2 Change in the specification parameters and/or limits of the immediate packaging of the finished product - B.II.e.2.z Other changes - Accepted B.II.b.3 Change in the manufacturing process of the finished product, including an intermediate used in the manufacture of the finished product - B.II.b.3.z Other changes - Accepted B.I.a.2 Changes in the manufacturing process of the active substance - B.I.a.2.a Minor change in the manufacturing process of the active substance - Accepted B.I.a.2 Changes in the manufacturing process of the active substance - B.I.a.2.a Minor change in the manufacturing process of the active substance - Accepted | 13/08/2025 | N/A |

<div style=\"page-break-after: always\"></div>

|                                       | B.I.a.1 Change in the manufacturer of a starting material/reagent/intermediate used in the manufacturing process of the active substance or change in the manufacturer (including where relevant quality control testing sites) of the active substance, where no Ph. Eur. Certificate of Suitability is part of the approved dossier - B.I.a.1.z Other variation - Accepted                                                                                                                           |            |                                                                                                                                                                                                                                                                                                      |
|---------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Variation type II / EMA/VR/0000249246 | This was an application for a group of variations. B.II.d.2 Change in test procedure for the finished product - B.II.d.2.a Minor changes to an approved test procedure - Accepted B.II.d.2 Change in test procedure for the finished product - B.II.d.2.c Substantial change to, or replacement of, a biological/ immunological/ immunochemical test method or a method using a biological reagent or replacement of a biological reference preparation not covered by an approved protocol - Accepted | 25/04/2025 | B.II.d.2.a Minor changes to an approved test procedure. B.II.d.2.c Substantial change to, or replacement of, a biological/ immunological/ immunochemical test method or a method using a biological reagent or replacement of a biological reference preparation not covered by an approved protocol |
| PSUR / EMA/PSUR/0000288269            | - -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |            | Maintenance                                                                                                                                                                                                                                                                                          |